Sartorius AG Extends Executive Board Member's Appointment Through 2031

The Supervisory Board of Sartorius AG has resolved to extend the appointment of Dr. René Fáber as a member of the Executive Board by a five-year period to December 31, 2031. This decision ensures leadership continuity for the company's Bioprocess Solutions Division, which Fáber has led since his initial appointment to the board in January 2019. The extension comes as Sartorius continues to serve as a leading international partner to the biopharmaceutical research and manufacturing industries, with the Bioprocess Solutions Division providing critical single-use solutions for the production of biotech drugs, vaccines, and cell and gene therapies.

Fáber brings extensive institutional knowledge to his continued role, having joined Sartorius as a scientist in 2002 and progressed through several management positions before his executive appointment. His academic background includes a Ph.D. in polymer chemistry from the Technical University of Munich. The leadership stability provided by this extension is particularly significant given Sartorius's position in the competitive bioprocessing market, where the company supports customers with a broad product portfolio focused on safer, faster, and more sustainable production methods. This continuity supports the company's strategic direction as it maintains approximately 60 production and sales locations worldwide and serves customers globally with more than 14,000 employees.

The timing of this announcement coincides with key financial reporting periods for the company, including the upcoming publication of first quarter results on April 23, 2026. Sartorius generated sales revenue of around 3.5 billion euros in 2025, demonstrating the substantial scale of operations that Fáber will continue to help oversee. The company's Lab Products & Services Division complements the Bioprocess Solutions Division by focusing on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies, a strategy that requires consistent executive leadership to implement successfully.

This board appointment extension reflects confidence in Fáber's leadership during a period of continued growth and innovation in the biopharmaceutical sector. The decision ensures that the Bioprocess Solutions Division will maintain its strategic direction as it supports the evolving needs of the healthcare industry. Additional information about the company's leadership and financial performance can be found through its official communications channels and financial calendar. The extension through 2031 provides long-term stability for Sartorius as it continues to expand its global presence and technological capabilities in serving the biopharmaceutical industry's complex manufacturing and research requirements.